Clinical Trial Update: A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of the PARP inhibitor DAT-2645 monotherapy for advanced/metastatic solid tumors harboring BRCA1/2 loss-of-f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• DAT-2645

Snippet

Sponsor: Danatlas Pharmaceuticals Co., Ltd | Conditions: Solid Cancers, BRCA Mutation | Phase 1 | Status: NOT_YET_RECRUITING